Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
---|---|---|---|
USD 11.52 Billion | USD 24.87 Billion | 8% | 2024 |
The global cancer biological therapy market size was worth around USD 11.52 Billion in 2024 and is predicted to grow to around USD 24.87 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 8% between 2025 and 2034.
The report analyzes the global cancer biological therapy market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the cancer biological therapy industry.
Biological therapy or biotherapy is a new cancer treatment method. It makes use of biological response modifiers as well as biologicals for treating cancer. Moreover, biological response modifiers or biologicals originate from mammalian cells and improve the immune response. The launching of molecular biological procedures and hybridoma technology has resulted in the preparation of these substances in huge quantities and highly pure form to apply them in cancer biological therapy. Additionally, nanomedicine provides a tool of biocompatible systems that can provide traditional chemotherapeutic medicines in vivo along with raising their bioavailability around the cancerous tumors and increasing their release profile. Reportedly, nanoparticles can be used for oncology applications that range from diagnosis to treatment.
The surge in cancer occurrence to boost the global market demand across the globe over 2025-2034
Cancer is one of the key causes of death across the globe and in the last few years, a large number of research studies have demonstrated the necessity of introducing new treatments for reducing the side effects due to traditional therapies. This aspect is predicted to drive the global cancer biological therapy market trends. Moreover, cancer biological therapies like oncolytic virus therapy and immunotherapy are well tolerated by the bodies of the patients and have low side effects as compared to chemotherapies due to their effective immune tolerance mechanisms. This will help the market scale up new terrains of growth over the forecast timespan.
Furthermore, the rise in the incurrence of cancer, the surging impact of biosimilars, and the escalating need for targeted drug treatments will steer the expansion of the market over the forthcoming years. Huge funding for cancer research projects and government aid for developing new cancer treatments will amplify the growth rate of the market in the years to come. Launching of new cancer biologics & drug discovery platforms for treating cancer will further contribute to the global market demand in the years to come. For instance, in August 2023, TFC Therapeutics, a biotech firm manufacturing biologics for targeting and eliminating cancer, launched a drug discovery tool targeting tumor macrophage hybrid cells in collaboration with Columbia University.
Side effects of treatment in patients can prove detrimental to the global industry expansion
Side effects witnessed in patients undergoing cancer biological treatment can impede the expansion of the cancer biological therapy industry across the globe. For instance, the most common infections caused due to cancer biological therapy include upper respiratory tract infections, heart ailments, and an increase in the levels of triglyceride witnessed in the patients.
Rise in fundraising and investments for developing innovative cancer treatment modes to open new growth avenues for the global market
A surge in the funding by government and private institutions for improving the healthcare infrastructure & biotech facilities of the country has transformed into innovations in the modes of cancer treatment. This has increased the scope of demand for cancer biological therapy, thereby helping the cancer biological therapy market explore new horizons of growth globally. In addition to this, a rise in fundraising activities for developing new methods of treating cancer will help the global market reach ascending heights of growth.
Huge treatment costs and low availability of professionals can put up a huge challenge in the growth path of the industry across the globe
The rise in the costs of treatment and the low availability of skilled persons can prove to be a huge challenge for the global cancer biological therapy industry. Apart from this, the easy availability of alternate modes of treatment which are cost-effective can further pose a threat to the global industry surge.
The global cancer biological therapy market is sectored into application, product type, and region.
In application terms, the global cancer biological therapy market is segregated into diagnostic laboratories, hospitals, pharmaceutical & biotechnology companies, and research & academic laboratories segments. Moreover, the hospitals segment, which garnered nearly 55% of the global market share in 2022, is projected to record the fastest CAGR in the projected timeline. The growth of the segment in the next few years can be due to the rise in the use of cancer biological therapy in hospitals for treating patients.
Based on the product type, the global cancer biological therapy industry is bifurcated into monoclonal antibodies, cancer growth blockers, vaccines, blood cell growth factors, and cytokine segments. In addition to this, the monoclonal antibodies segment, which contributed about half of the global industry share in 2022, is set to establish segmental dominance in the assessment period. The segmental elevation over the analysis timeframe can be subject to the ability of the product to target particular proteins on the surface of the cell, thereby enhancing its use in cancer treatment. Additionally, the rise in the preference for advanced cancer biological treatment for preventing side effects of the anti-cancer drug treatment mode has boosted the demand for monoclonal antibodies.
By Route of Administration, the global cancer biological therapy market is split into Oral, Injectable.
In terms of Distribution Channel, the global cancer biological therapy market is categorized into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Report Attributes | Report Details |
---|---|
Report Name | Cancer Biological Therapy Market |
Market Size in 2024 | USD 11.52 Billion |
Market Forecast in 2034 | USD 24.87 Billion |
Growth Rate | CAGR of 8% |
Number of Pages | 225 |
Key Companies Covered | Bristol-Myers Squibb, Spectrum Pharmaceuticals, Amgen, F. Hoffmann-La Roche, AbbVie, AstraZeneca, Novartis AG, Astellas, Pfizer, Celgene Corporation, Sanofi, Takeda Pharmaceuticals, Bayer, ELI Lilly & Company, Eisai, GlaxoSmithKline, Merck, Incyte, Otsuka, and Seattle Genetics., and others. |
Segments Covered | By Type, By Application, By Route of Administration, By Distribution Channel, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, The Middle East and Africa (MEA) |
Base Year | 2024 |
Historical Year | 2020 to 2023 |
Forecast Year | 2025 - 2034 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America to contribute majorly towards global market Share Over 2025-2034
The growth of the cancer biological therapy market in North America over the forecast timeframe can be subject to an increase in the incidences of cancer witnessed in countries like the U.S. In addition to this, an increase in the proportion of the aging populace prone to chronic ailments like cancer will prompt the regional market surge in the coming years. The presence of strong healthcare infrastructure in the region along with favorable compensation policies will help the regional market record stupendous growth. Affordable healthcare insurance and cutting-edge gene therapies will enable the market in North America to witness a mammoth expansion.
The European cancer biological therapy industry is set to register the fastest CAGR over the forecast timeline owing to the rise in awareness about oncology among the people along with growing demand for advanced cancer therapies in the continent. Apart from this, the presence of key players in the countries of Europe will majorly contribute to the industry expansion in the continent in the years to come.
The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the cancer biological therapy market on a global and regional basis.
The global cancer biological therapy market is dominated by players like:
By Type
By Application
By Route of Administration
By Distribution Channel
By Region
FrequentlyAsked Questions
The global cancer biological therapy market is expected to grow due to Increasing cancer prevalence and shift towards targeted, less toxic treatments drive demand. Biotech innovations and personalized medicine approaches support market growth.
According to a study, the global cancer biological therapy market size was worth around USD 11.52 Billion in 2024 and is expected to reach USD 24.87 Billion by 2034.
The global cancer biological therapy market is expected to grow at a CAGR of 8% during the forecast period.
North America is expected to dominate the cancer biological therapy market over the forecast period.
Leading players in the global cancer biological therapy market include Bristol-Myers Squibb, Spectrum Pharmaceuticals, Amgen, F. Hoffmann-La Roche, AbbVie, AstraZeneca, Novartis AG, Astellas, Pfizer, Celgene Corporation, Sanofi, Takeda Pharmaceuticals, Bayer, ELI Lilly & Company, Eisai, GlaxoSmithKline, Merck, Incyte, Otsuka, and Seattle Genetics., among others.
The report explores crucial aspects of the cancer biological therapy market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed